Inhibition of indoleamine 2,3-dioxygenase 1 expression alters immune response in colon tumor microenvironment in mice

Cancer Science

Volumn 106, Issue 8, 2015, Pages 1008-1015

  Takamatsu, Manabu ^a,e   Hirata, Akihiro ^b   Ohtaki, Hirofumi ^a,f   Hoshi, Masato ^c   Ando, Tatsuya ^a   Ito, Hiroyasu ^a   Hatano, Yuichiro ^a   Tomita, Hiroyuki ^a   Kuno, Toshiya ^a,g   Saito, Kuniaki ^d   Seishima, Mitsuru ^a   Hara, Akira ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GIFU UNIVERSITY   (Japan)

^c SUZUKA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^d KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e CANCER INSTITUTE   (Japan)

^f KANSAI UNIVERSITY OF HEALTH SCIENCES   (Japan)

^g NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Cancer immunity; Colorectal cancer; Indoleamine 2,3 dioxygenase; Microenvironment; Tumorigenesis

Indexed keywords

1 METHYLTRYPTOPHAN; CYTOKINE; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3; TRYPTOPHAN; TRYPTOPHAN DERIVATIVE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; IDO1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RECURRENCE; COLON ADENOCARCINOMA; COLON ADENOMA; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; ENZYME INHIBITION; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SOLID TUMOR; TUMOR DIFFERENTIATION; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; C57BL MOUSE; COLON TUMOR; ENZYMOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; COLONIC NEOPLASMS; ENZYME INHIBITORS; IMMUNOHISTOCHEMISTRY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR MICROENVIRONMENT;

EID: 84939266366     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12705     Document Type: Article

References (45)

1. Lob S, Konigsrainer A, Rammensee HG, Opelz G, Terness P. Inhibitors of indoleamine-2, 3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer 2009; 9: 445-52.
2. Ball HJ, Yuasa HJ, Austin CJ, Weiser S, Hunt NH. Indoleamine 2, 3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int J Biochem Cell Biol 2009; 41: 467-71.
3. Fallarino F, Grohmann U, Vacca C et al. T cell apoptosis by kynurenines. Adv Exp Med Biol 2003; 527: 183-90.
4. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999; 189: 1363-72.
5. Opitz CA, Litzenburger UM, Opitz U et al. The indoleamine-2, 3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells. PLoS ONE 2011; 6: e19823.
6. Uyttenhove C, Pilotte L, Theate I et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat Med 2003; 9: 1269-74.
7. Brandacher G, Perathoner A, Ladurner R et al. Prognostic value of indoleamine 2, 3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 2006; 12: 1144-51.
8. Ferdinande L, Decaestecker C, Verset L et al. Clinicopathological significance of indoleamine 2, 3-dioxygenase 1 expression in colorectal cancer. Br J Cancer 2012; 106: 141-7.
9. Gao YF, Peng RQ, Li J et al. The paradoxical patterns of expression of indoleamine 2, 3-dioxygenase in colon cancer. J Transl Med 2009; 7: 71.
10. Ino K, Yoshida N, Kajiyama H et al. Indoleamine 2, 3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 2006; 95: 1555-61.
11. Takao M, Okamoto A, Nikaido T et al. Increased synthesis of indoleamine-2, 3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer. Oncol Rep 2007; 17: 1333-9.
12. Pan K, Wang H, Chen MS et al. Expression and prognosis role of indoleamine 2, 3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol 2008; 134: 1247-53.
13. Chang MY, Smith C, DuHadaway JB et al. Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2, 3-dioxygenase. Cancer Biol Ther 2011; 12: 1050-8.
14. Thaker AI, Rao MS, Bishnupuri KS et al. IDO1 metabolites activate beta-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice. Gastroenterol 2013; 145: 416-25 e1-4.
15. Gurtner GJ, Newberry RD, Schloemann SR, McDonald KG, Stenson WF. Inhibition of indoleamine 2, 3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterol 2003; 125: 1762-73.
16. Takamatsu M, Hirata A, Ohtaki H et al. IDO1 plays an immunosuppressive role in 2, 4, 6-trinitrobenzene sulfate-induced colitis in mice. J Immunol 2013; 191: 3057-64.
17. Wolf AM, Wolf D, Rumpold H et al. Overexpression of indoleamine 2, 3-dioxygenase in human inflammatory bowel disease. Clin Immunol 2004; 113: 47-55.
18. Zhou L, Chen H, Wen Q, Zhang Y. Indoleamine 2, 3-dioxygenase expression in human inflammatory bowel disease. Eur J Gastroenterol Hepatol 2012; 24: 695-701.
19. Hata K, Yamada Y, Kuno T et al. Tumor formation is correlated with expression of beta-catenin-accumulated crypts in azoxymethane-induced colon carcinogenesis in mice. Cancer Sci 2004; 95: 316-20.
20. Papanikolaou A, Wang QS, Papanikolaou D, Whiteley HE, Rosenberg DW. Sequential and morphological analyses of aberrant crypt foci formation in mice of differing susceptibility to azoxymethane-induced colon carcinogenesis. Carcinogenesis 2000; 21: 1567-72.
21. Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 2003; 94: 965-73.
22. Hoshi M, Osawa Y, Ito H et al. Blockade of indoleamine 2, 3-dioxygenase reduces mortality from peritonitis and sepsis in mice by regulating functions of CD11b+ peritoneal cells. Infect Immun 2014; 82: 4487-95.
23. Archer MC, Bruce WR, Chan CC et al. Aberrant crypt foci and microadenoma as markers for colon cancer. Environ Health Perspect 1992; 98: 195-7.
24. Hoshi M, Saito K, Hara A et al. The absence of IDO upregulates type I IFN production, resulting in suppression of viral replication in the retrovirus-infected mouse. J Immunol 2010; 185: 3305-12.
25. Sakai H, Yamada Y, Shimizu M, Saito K, Moriwaki H, Hara A. Genetic ablation of Tnfalpha demonstrates no detectable suppressive effect on inflammation-related mouse colon tumorigenesis. Chem Biol Interact 2010; 184: 423-30.
26. Lob S, Konigsrainer A, Zieker D et al. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother 2009; 58: 153-7.
27. Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR. The indoleamine 2, 3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol 2008; 181: 5396-404.
28. Akeus P, Langenes V, von Mentzer A et al. Altered chemokine production and accumulation of regulatory T cells in intestinal adenomas of APC(Min/+) mice. Cancer Immunol Immunother 2014; 63: 807-19.
29. Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2, 3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 2007; 67: 7082-7.
30. Austin CJ, Mailu BM, Maghzal GJ et al. Biochemical characteristics and inhibitor selectivity of mouse indoleamine 2, 3-dioxygenase-2. Amino Acids 2010; 39: 565-78.
31. Pantouris G, Serys M, Yuasa HJ, Ball HJ, Mowat CG. Human indoleamine 2, 3-dioxygenase-2 has substrate specificity and inhibition characteristics distinct from those of indoleamine 2, 3-dioxygenase-1. Amino Acids 2014; 46: 2155-63.
32. Lee YK, Lee HB, Shin DM et al. Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2, 3-dioxygenase 1 (IDO1) by IDO2. Exp Mol Med 2014; 46: e121.
33. Grivennikov SI. Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol 2013; 35: 229-44.
34. Ciorba MA, Bettonville EE, McDonald KG et al. Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. J Immunol 2010; 184: 3907-16.
35. Matteoli G, Mazzini E, Iliev ID et al. Gut CD103+ dendritic cells express indoleamine 2, 3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction. Gut 2010; 59: 595-604.
36. Metz R, Smith C, DuHadaway JB et al. IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. Int Immunol 2014; 26: 357-67.
37. Zaher SS, Germain C, Fu H, Larkin DF, George AJ. 3-hydroxykynurenine suppresses CD4+ T-cell proliferation, induces T-regulatory-cell development, and prolongs corneal allograft survival. Invest Ophthalmol Vis Sci 2011; 52: 2640-8.
38. Wainwright DA, Balyasnikova IV, Chang AL et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res 2012; 18: 6110-21.
39. Yu J, Sun J, Wang SE et al. Upregulated expression of indoleamine 2, 3-dioxygenase in primary breast cancer correlates with increase of infiltrated regulatory T cells in situ and lymph node metastasis. Clin Dev Immunol 2011; 2011: 469135.
40. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007; 117: 1167-74.
41. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privi lege and predicts reduced survival. Nat Med 2004; 10: 942-9.
42. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137-48.
43. Ramos RN, Oliveira CE, Gasparoto TH et al. CD25+ T cell depletion impairs murine squamous cell carcinoma development via modulation of antitumor immune responses. Carcinogenesis 2012; 33: 902-9.
44. Pastille E, Bardini K, Fleissner D et al. Transient ablation of regulatory T cells improves antitumor immunity in colitis-associated colon cancer. Cancer Res 2014; 74: 4258-69.
45. Ishio T, Goto S, Tahara K, Tone S, Kawano K, Kitano S. Immunoactivative role of indoleamine 2, 3-dioxygenase in human hepatocellular carcinoma. J Gastroenterol Hepatol 2004; 19: 319-26.